- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Hypha Labs, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 11.08. | Hypha Labs, Inc.: Hypha Labs Expands List of Functional Mushrooms Able to be Produced in its Revolutionary Mushroom Accelerator | 176 | ACCESS Newswire | Simple, In-Home Eight Day Cycle Generates Significant Yields of The World's Most Popular Mushroom Strains LAS VEGAS, NV / ACCESS Newswire / August 11, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an A.I. powered... ► Artikel lesen | |
| 28.07. | Hypha Labs, Inc.: Hypha Labs Provides Shareholder Update | 667 | ACCESS Newswire | LAS VEGAS, NEVADA / ACCESS Newswire / July 28, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls... ► Artikel lesen | |
| HYPHA LABS Aktie jetzt für 0€ handeln | |||||
| 13.06. | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.06. | Hypha Labs, Inc.: Hypha Labs Files New Patent Application for Its Suite of Artificial Intelligence Techniques for Its Mushroom Accelerator | 380 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / June 10, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls suite... ► Artikel lesen | |
| 15.05. | Hypha Labs, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings | ||
| 13.05. | Hypha Labs, Inc.: Hypha Labs Files Multiple Additional Patents for its Ground Breaking Mushroom Accelerator | 307 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / May 13, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls suite of products, is pleased to announce... ► Artikel lesen | |
| 12.05. | Hypha Labs Inc. and Emerging Markets Consulting LLC: Emerging Markets Report: A Milestone for Mycelium | 1 | GlobeNewswire (USA) | ||
| 01.05. | Hypha Labs, Inc.: Hypha Labs Acquires State-of-the-Art HPLC Analytic Machine and Partners with Lucidity Systems for Advanced Autosampler Upgrade | 419 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / May 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls suite of products, is pleased to announce... ► Artikel lesen | |
| 22.04. | Hypha Labs and the technology behind micropearls | 2 | The Market Herald Canada | ||
| 09.04. | Hypha Labs, Inc.: New Mexico Governor Signs Bill Allowing for Psilocybin Use | 283 | ACCESS Newswire | 'Medical Psilocybin Act' Provides Legal Access to Citizens for the First Time LAS VEGAS, NV / ACCESS Newswire / April 9, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences... ► Artikel lesen | |
| 17.03. | Hypha Labs, Inc.: Hypha Laboratories Retains Stockhouse for International Awareness Campaign | 265 | ACCESS Newswire | Venerable, Popular Destination to Introduce Hypha Labs to Canadian and U.S. Investors LAS VEGAS, NV / ACCESS Newswire / March 17, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
| 30.01. | Hypha Labs, Inc.: Hypha Laboratories Reports Significant Breakthrough for MicroPearls Yields | 304 | ACCESS Newswire | In-Home Consumer Harvests Increase Exponentially After Research Discovery at Hypha Laboratories LAS VEGAS, NEVADA / ACCESS Newswire / January 30, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional... ► Artikel lesen | |
| 27.01. | Hypha Labs, Inc.: Hypha Laboratories Applauds Call for Regulatory Changes for Functional Mushrooms | 281 | ACCESS Newswire | Legislative Changes Usher Acceptance, Broaden Market Opportunity for Early Adopters LAS VEGAS, NV / ACCESS Newswire / January 27, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
| 18.11.24 | Hypha Labs, Inc.: Hypha Laboratories Announces Completion of Phase 1 of Its State-of-the-Art Facility and Arrival of V5 Working MicroPearls Prototypes | 326 | ACCESS Newswire | Advancements Enhance Efficacy in Hypha's Revolutionary Home and Commercial Production UnitsLAS VEGAS, NV / ACCESSWIRE / November 18, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
| 15.10.24 | Hypha Labs, Inc.: Hypha Laboratories Establishes Scientific and Cultural Advisory Board, Adds William Padilla-Brown | 322 | ACCESS Newswire | Board Will Add to Company's Intellectual Capital and Diversity of ExperienceLAS VEGAS, NV / ACCESSWIRE / October 15, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and... ► Artikel lesen | |
| 07.10.24 | Hypha Labs, Inc.: Hypha Laboratories Reveals New Patent Applications for Novel A.I. Driven In-Home Mycelium Production | 313 | ACCESS Newswire | Company Intends to Bring First Functional Mushroom Producer to RetailLAS VEGAS, NV / ACCESSWIRE / October 7, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator... ► Artikel lesen | |
| 30.09.24 | Hypha Labs, Inc. Reveals First Functional Mushroom Ingredient Array for Home and Commercial Production | 291 | ACCESS Newswire | First Generation 'MicroPearls Pro'and "MicroPearls ProX" Will Support Largest Mushroom Ingredient CategoriesLAS VEGAS, NV / ACCESSWIRE / September 30, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer... ► Artikel lesen | |
| 26.09.24 | Hypha Labs, Inc.: Functional Mushroom Company Hypha Labs Retains Emerging Markets Consulting LLC for Investor Relations Advisory Services | 292 | ACCESS Newswire | LAS VEGAS, NV / ACCESSWIRE / September 26, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences, is pleased to announce that the Company has retained Emerging Markets Consulting... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 46,350 | +3,78 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| QIAGEN | 42,550 | -0,07 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen nach einer Investorenveranstaltung auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Das Interesse der Teilnehmer... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,940 | +3,35 % | Why Recursion Pharmaceuticals Stock Caught a Cold This Week | ||
| EVOTEC | 6,116 | 0,00 % | Aktien KW 34 Nix passiert? Montag Powell Schub? Aber: Woher die guten Nachrichten? Nvdia am Mittwoch als Lackmustest? Märkte heissgelaufen? News. Rheinmetall. Evotec. Stratec. YOC. Doc Morris. SFC Energy. Multitude. Circus. Delignit. Lang und Schwarz. Kap | Aktien: Diese Woche hnadelte der Markt in einer engen Range von unter 300 Punkten. Schien alles auf Powell's Rede zu warten. Und für die Bullen scheint es sich gelohnt zu haben, die Auguren deuteten... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 33,750 | +0,51 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 14,885 | +1,88 % | Jefferies belässt Mineralys auf 'Hold' und blickt auf entscheidende Daten von AstraZeneca | ||
| SUMMIT THERAPEUTICS | 26,200 | +0,73 % | Summit Therapeutics: UBS bestätigt Kaufempfehlung vor wichtigen Studiendaten | ||
| BIONTECH | 95,75 | +0,68 % | BioNTech Aktie: Entscheidung an dieser Kursmarke! Steht die große Wende bevor? | © Foto: Bild von felixioncool auf PixabayBioNTech kennt jeder als Corona-Impfstoff-Pionier. Doch längst arbeitet das Mainzer Unternehmen fieberhaft an der nächsten Revolution: Krebs soll mit derselben... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,640 | +3,94 % | Cantor Fitzgerald reiterates Overweight rating on Beam Therapeutics stock | ||
| VALNEVA | 5,045 | -0,20 % | Valneva: Kanada weitet Zulassung für Chikungunya-Vakzin aus | Valneva hat von Health Canada eine erweiterte Zulassung für seinen Chikungunya-Impfstoff IXCHIQ erhalten, der nun für Personen ab 12 Jahren angewendet werden darf. Damit erweitert sich die bisherige... ► Artikel lesen | |
| COGNITION THERAPEUTICS | 2,790 | +40,20 % | Cognition Therapeutics, Inc.: Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease | - Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:... ► Artikel lesen | |
| TEMPUS AI | 68,50 | -0,72 % | Tempus AI: KI-Aktie wie entfesselt nach Zahlen | Der KI-Spezialist Tempus AI hat vor wenigen Handelstagen einen überzeugenden Bericht zum zweiten Quartal vorgelegt. Seitdem kennt die Aktie des Unternehmens, welches erst vor rund zehn Jahren in Chicago... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,800 | +4,09 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| BIOVENTUS | 7,640 | +7,91 % | Bioventus, Inc.: Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products | DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug... ► Artikel lesen | |
| LIMINATUS PHARMA | 3,410 | +22,66 % | Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies | LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen |
HYPHA LABS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HYPHA LABS INC finden Sie auf Wallstreet Online.